Orthocell AAQS

Co robi Orthocell? Orthocell Ltd, listed on the Australian Securities Exchange under the ticker OCC.AX, is a biotechnology company headquartered in Perth, Western Australia. The company went public via an IPO on August 12, 2014. Orthocell focuses on developing and commercializing cell therapies and related technologies aimed at regenerating mobility for patients with bone and soft tissue injuries. Its product portfolio includes CelGro, a collagen medical device designed for tissue reconstruction and healing in dental and orthopedic applications. CelGro is manufactured using a SMRT process to maintain the natural collagen structure. The company also offers Striate+ for dental guided bone regeneration, Remplir for peripheral nerve reconstruction, and SmrtGraft for tendon repair. Orthocell is developing an autologous cell therapy focused on regenerating damaged tendon and cartilage tissue, with an advanced injectable cellular therapy for chronic tendon injuries currently under development in the United States. The company's website is www.orthocell.com.au, and it operates within the healthcare sector, specifically in biotechnology. Orthocell's business model centers on creating innovative solutions for tissue repair and regeneration, targeting both clinical and commercial applications in the medical field. Orthocell jest jedną z najpopularniejszych firm na Eulerpool.